Progress in the Treatment of Metastatic Melanoma

Published Online: Wednesday, September 26, 2012
Follow Pharmacy_Times:
In this podcast, a panel of experts discusses a range of topics relating to metastatic melanoma, including new treatment approaches, clinical trial updates, and managing side effects and pain. The participants on the panel were: Paul Chapman, MD, of the Memorial Sloan-Kettering Cancer Center; Gregory Daniels, MD, PhD, of the University of California San Diego; Mario Lacouture, MD, of the Memorial Sloan-Kettering Cancer Center; and Carolyn Messner, DSW, MSW, of CancerCare.
 
To listen to the podcast, click here.
Related Articles
Taking more nutritional supplements than needed may increase a patient’s risk of cancer.
The FDA today approved a second-line treatment for metastatic colorectal cancer.
The FDA has awarded Breakthrough Therapy status to crizotinib (Xalkori) for ROS1-positive non-small cell lung cancer.
The FDA has granted Orphan Drug Designation to AstraZeneca’s selumetinib.
Latest Issues
  • photo
    Pharmacy Times
    photo
    Health-System Edition
    photo
    Directions in Pharmacy
    photo
    OTC Guide
    photo
    Generic Supplements
  • photo
    Pharmacy Careers
    photo
    Specialty Pharmacy Times
    photo
    Generic
$auto_registration$